NEW YORK, June 17 - Schering has extended a collaboration with Atugen of Berlin to validate drug targets associated with cancer using Atugen's KnockDown technology.
The two companies have been collaborating for six years so far. The new agreement adds two more years to the partnership, and has been expanded to include Atugen's RNA interference technology. Atugen will develop its GeneBloc antisense molecules and/or siRNA molecules that are designed to inhibit expression of drug target candidates selected by Schering. Atugen will analyze the effects of the knockdown to validate gene function and disease association.
Under the terms of the new agreement, Atugen will receive annual licensing fees, research funding, and milestone payments.
Atugen will be working with Schering's research scientists in Germany and its Berlex Biosciences subsidiary in California.